Scarica l'app Stockscreener
16.98
9.76%
1.51
Uniqure N V Borsa (QURE) Ultime notizie
(QURE) Technical Pivots with Risk Controls - Stock Traders Daily
uniQure (NASDAQ:QURE) Trading Up 5.8% on Analyst Upgrade - MarketBeat
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug - MSN
uniQure (NASDAQ:QURE) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
CSL and uniQure Win 2023 Prix Galien USA Award - GuruFocus.com
57,333 Shares in uniQure (NASDAQ:QURE) Purchased by Y Intercept Hong Kong Ltd - MarketBeat
Around the Helix: Cell and Gene Therapy Company Updates – December 18, 2024 - CGTLive™
uniQure price target raised to $32 from $12 at Stifel - Yahoo Finance
uniQure (NASDAQ:QURE) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
uniQure (NASDAQ:QURE) Price Target Raised to $32.00 at Stifel Nicolaus - MarketBeat
uniQure (NASDAQ:QURE) Shares Acquired by Fmr LLC - MarketBeat
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? - Yahoo Finance
uniQure (NASDAQ:QURE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
uniQure (NASDAQ:QURE) Trading 5.2% Higher Following Analyst Upgrade - MarketBeat
uniQure FY2024 EPS Estimate Reduced by Leerink Partnrs - MarketBeat
Biotech Alert: Searches spiking for these stocks today - TipRanks
Real-World Evidence Helps Open Accelerated Approval Pathway For Neurodegeneration Therapies - News & Insights
QURE (uniQure NV) Free Cash Flow : $-193.09 Mil (TTM As of Sep. 2024) - GuruFocus.com
Wells Fargo & Company Upgrades uniQure (NASDAQ:QURE) to "Strong-Buy" - MarketBeat
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More - MSN
Goldman maintains Neutral rating on uniQure shares, cites FDA review By Investing.com - Investing.com Nigeria
Goldman maintains Neutral rating on uniQure shares, cites FDA review - Investing.com
UniQure Stock Hits 52-Week High at $13.72 Amidst Modest Annual Growth - Investing.com Canada
uniQure (NASDAQ:QURE) Shares Sold by Verition Fund Management LLC - MarketBeat
Raymond James Upgrades uniQure N.V. (QURE) - MSN
uniQure (NASDAQ:QURE) Upgraded to Sell at StockNews.com - MarketBeat
UniQure Stock Hits 52-Week High at $13.72 Amidst Modest Annual Growth By Investing.com - Investing.com South Africa
UniQure: Accelerated Approval Plan With US FDA May Save Five Years - Citeline
uniQure CFO Christian Klemt sells $13,559 in stock By Investing.com - Investing.com Nigeria
Uniqure stock doubles as FDA points to a BLA in Huntington’s - BioWorld Online
uniQure CFO Christian Klemt sells $13,559 in stock - Investing.com
uniQure CEO Matthew Kapusta sells $26,079 in stock By Investing.com - Investing.com Nigeria
uniQure’s AMT-130: A Bold Step For Huntington’s, But Not Without Hurdles (NASDAQ:QURE) - Seeking Alpha
uniQure CEO Matthew Kapusta sells $26,079 in stock - Investing.com India
uniQure stock boosted by FDA alignment on accelerated approval for AMT-130 - Investing.com
UniQure doubles on alignment with FDA on development plan for gene therapy - XM
uniQure Soars 111% on FDA Approval - Wall Street Pit
Gene therapy developer's stock doubles after FDA grants accelerated approval - The Business Journals
Raymond James, Cantor bullish on uniQure following FDA update (NASDAQ:QURE) - Seeking Alpha
UniQure (QURE) Stock Soars Over 121% on FDA Approval Pathway - GuruFocus.com
uniQure soars as it aligns regulatory path for Huntington’s candidate AMT-130 - The Pharma Letter
uniQure stock rockets 90% on FDA update for AMT-130 (NASDAQ:QURE) - Seeking Alpha
UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment - Marketscreener.com
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday - Benzinga
uniQure shares surge on FDA accelerated approval pathway accord By Investing.com - Investing.com South Africa
uniQure aligns with FDA on Accelerated Approval for AMT-130 - Investing.com India
uniQure shares surge on FDA accelerated approval pathway accord - Investing.com India
uniQure aligns with FDA on Accelerated Approval for AMT-130 By Investing.com - Investing.com Canada
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease - The Manila Times
uniQure Announces Alignment with FDA on Key Elements of - GlobeNewswire
UniQure shares soar on chance of speedy approval for Huntington’s therapy - Yahoo Finance
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in - EIN News
When the Price of (QURE) Talks, People Listen - Stock Traders Daily
uniQure (NASDAQ:QURE) Stake Increased by Point72 Asset Management L.P. - MarketBeat
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):